Can Fite Biofarma (XTAE:CANF) Net Income From Continuing Operations : ₪-11.96 Mil (TTM As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Can Fite Biofarma's net income from continuing operations for the three months ended in Dec. 2024 was ₪0.00 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was ₪-11.96 Mil.

Can Fite Biofarma Net Income From Continuing Operations Historical Data

The historical data trend for Can Fite Biofarma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Net Income From Continuing Operations Chart

Can Fite Biofarma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-50.59

-44.18

-35.63

-26.74

-27.60

Can Fite Biofarma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-5.85	-6.17	-5.79	-	-

Can Fite Biofarma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-11.96 Mil.

Can Fite Biofarma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

26 Ben Gurion Street, Ramat Gan, ISR, 5257346

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).